


# Exponential Technologies Fund

## Fact Sheet

December 31, 2025

Class I: **ETIEX** | Class A: **ETAEV** | Class C: **ETCEX** | Class N: **ETNEX**

**The Eventide Exponential Technologies Fund** seeks to provide long-term capital appreciation by investing at least 80% of its net assets (under normal market conditions) in companies we believe are participating in and benefiting from technologies, innovations, technology themes, or technology trends.



*This is a hypothetical illustration and is not intended to reflect the actual performance of any particular account. Future performance cannot be guaranteed and investment returns will fluctuate with market conditions.*

Trailing Returns <sup>7</sup> (%)								12/31/2025
Eventide Exponential Technologies Fund		YTD	3-mos	1-year	3-year <sup>8</sup>	5-year <sup>8</sup>	10-year <sup>8</sup>	Since Inception <sup>8</sup>
Class I		8.94	1.18	8.94	13.80	-1.28	-	7.42
Class A without load		8.66	1.05	8.66	13.50	-1.51	-	7.17
Class A with 5.75% load		2.41	-4.75	2.41	11.29	-2.67	-	6.02
Class C		7.87	0.95	7.87	12.68	-2.26	-	6.38
Class N		8.73	1.12	8.73	13.55	-1.48	-	7.20
Benchmark								06/30/2020
Bloomberg US 2500 Technology Total Return Index <sup>3</sup>		14.32	0.87	14.32	18.73	5.69	-	11.48
								06/30/2020

Calendar Year Returns <sup>6 7</sup> (%)						2021-2025
	2021	2022	2023	2024	2025	
Eventide Exponential Technologies Fund I	15.64	-44.98	31.96	2.52	8.94	
Bloomberg US 2500 Technology Total Return Index <sup>3</sup>	10.66	-28.77	23.56	18.48	14.32	

*Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. This material must be read along with the Fund's prospectus, which may be obtained at [eventidefunds.com/prospectus](http://eventidefunds.com/prospectus). Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).*

1. Active Share is the percentage of fund holdings that is different from the benchmark holdings. A higher percentage indicates a greater difference from the benchmark.

2. The range shows the highest and lowest turnover ratio reported in the Annual Report during the last three fiscal years, ending 06/30/2025. Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year. A higher portfolio turnover may indicate higher transaction costs for the Fund, and may result in higher taxes for investors.

3. The Bloomberg US 2500 Technology Total Return Index is a float market-cap-weighted equity benchmark derived from membership of the Bloomberg US 2500 Index.

4. Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Funds prospectus, and should not be considered investment advice.

5. This chart is for illustrative purposes and assumes that a \$10,000 investment was made on the Fund's inception date of 06/30/2020 and that all dividends and capital gains were reinvested. Hypothetical performance often shows markedly better results than actual management and should not be the basis for an investment decision. A variety of factors could impact investment decision making or otherwise cause differences between the hypothetical performance and actual investor returns.


### FUND INFORMATION

Net Fund Assets:	\$91m
Number of Holdings:	53
Average Market Cap:	\$175.3 billion
Median Market Cap:	\$21.6 billion
Active Share <sup>1</sup> :	76%
Annual Turnover Range <sup>2</sup> :	70%-126%
Morningstar Category:	US Fund Technology
Benchmark <sup>3</sup> :	Bloomberg US 2500 Technology Total Return Index

### TOP HOLDINGS<sup>4</sup> (%)

<b>ServiceNow Inc (4.86%)</b>	Software for enterprises to manage and automate operational workflows
<b>Beta Bionics Inc (4.39%)</b>	Biotechnology company focused on developing bionic pancreas
<b>Taiwan Semiconductor Manufacturing Company Ltd (4.19%)</b>	Global semiconductor manufacturer
<b>Guardant Health Inc (4.05%)</b>	Cell diagnostics for cancer patients
<b>Intuit Inc. (3.97%)</b>	Develops and markets financial management software
<b>Toast Inc (3.87%)</b>	Develops cloud software to equip restaurants to thrive
<b>ServiceTitan (3.33%)</b>	Provides cloud software for the trades
<b>Axon Enterprise Inc (3.30%)</b>	Provides technology and devices for law enforcement, including body cameras and TASERs
<b>HubSpot (3.21%)</b>	Provides a cloud-based CRM platform with tools for marketing, sales, service, and content management
<b>Arista Networks Inc (3.06%)</b>	Networking company specializing in cloud-driven data center and enterprise solutions

OVERVIEW									12/31/2025
Fund	Nasdaq	Maximum Sales Charge	Management Fee <sup>2</sup>	Other Expenses <sup>3</sup>	12b-1 Fees	Gross Expenses <sup>4</sup>	Net Expenses <sup>5</sup>	Inception Date	
Class I	ETIEX	None	0.95%	0.59%	0.00%	1.54%	1.35%	6/30/2020	
Class A	ETAXX	Front-End: 5.75% <sup>1</sup>	0.95%	0.59%	0.25%	1.79%	1.60%	6/30/2020	
Class C	ETCEX	None <sup>1</sup>	0.95%	0.59%	1.00%	2.54%	2.35%	6/30/2020	
Class N	ETNEX	None	0.95%	0.59%	0.20%	1.74%	1.55%	6/30/2020	
Minimum Investment: \$100,000 (Class I <sup>6</sup> ), \$1,000 or \$100 with Automatic Investment Plan (Class A, C, N)									
Net Assets: \$91 million									



Market Risk <sup>7 11 12</sup>									12/31/2025
	Standard Deviation		Beta		Alpha(%)		R-Squared(%)		
	3-yr	Inception	3-yr	Inception	3-yr	Inception	3-yr	Inception	
Eventide Exponential Technologies I	21.75	25.06							
Bloomberg US 2500 Technology Total Return Index <sup>13</sup>	20.37	21.77							

1. Class A and Class C are also subject to a maximum deferred sales charge of 1.00%. This and other expenses that apply to a continued investment in the Fund are described in the Fund's prospectus.
2. Effective September 1, 2025, the management fee was reduced, as described in the Statement of Additional Information Supplement dated August 29, 2025
3. Refer to the Fund's SAI for definition of Other Expenses.
4. Effective September 1, 2025, the expenses were reduced, as described in the Statement of Additional Information Supplement dated August 29, 2025.
5. The adviser has contractually agreed to waive fees and/or reimburse expenses of the Fund through 10/31/2026. The agreement may be terminated by the Fund's Board of Trustees on 60 days' written notice.
6. Effective 06/01/2022, Class I shares purchased directly from the Funds are not subject to the minimum initial or subsequent investment requirements.
7. Source: © Morningstar, Inc. (2026). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

**Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results.** The Fund typically invests at least 80% of its net assets in companies that the Adviser believes are participating in and benefiting from technologies, innovations, technology themes, or technology trends which can include information technology, e-commerce discretionary, internet media and services, healthcare technology, healthcare devices, or transaction & payment processing services industries. The term "exponential" means the potential for accelerated advancements in underlying technologies that can positively impact capabilities and development cycles of a company's products and services. Not every company in the Fund's portfolio will experience exponential growth, and the Fund is not expected to deliver exponential returns. The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund may experience higher volatility than the general market due to being concentrated in the technology industries. Companies in the technology industries have

8. Allocation percentages are subject to change at any time, and should not be considered investment advice. Due to rounding, numbers may not add up to 100.
9. Impact bonds fund business models that strive to have significant social or environmental effects.
10. Includes cash, cash equivalents, money market funds and options.
11. The performance and risk factor comparisons are against the Bloomberg US 2500 Technology Total Return Index. Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of a fund relative to the return of the Index is a fund's alpha. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index. R-Squared is a measure of how a fund's performance correlates with the Index's performance and it can help assess how likely it is that beta is statistically significant. Standard Deviation of return measures the amount of variation in historical performance from period to period.
12. Annualized since inception figures use an inception date of 07/01/2020 and not the actual inception date of 06/30/2020 as only full month data is used in Market Risk calculations.
13. The Bloomberg US 2500 Technology Total Return Index is a float market-cap-weighted equity benchmark derived from membership of the Bloomberg US 2500 Index.

different risks including but not limited to products becoming obsolete, and entrance of competing products. Communications companies may underperform due to legislative or increased competition. Internet and Direct Marketing Retail companies may underperform due to legislative or increased government supervision. Healthcare Technology and Devices Companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the governments and regulatory authorities. Further, these companies are dependent on patent protection. The Fund has non-diversification risk as a high percentage of Fund assets may be invested in a limited number of companies. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.

## MANAGERS



**Finny Kuruvilla, MD, PhD** serves as Co-Chief Investment Officer and Senior Portfolio Manager for Eventide. He serves as the Lead Portfolio Manager for the Eventide Gilead Fund, the Eventide Healthcare & Life Sciences Fund, and the Eventide Exponential Technologies Fund. He also is a Managing Director for Eventide Ventures, as well as a Founding Member of Eventide. Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women's Hospital and Boston Children's Hospital, where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, an SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.



**Darric White** serves as Co-Portfolio Manager and Senior Research Analyst for Eventide's Technology Strategy. He is responsible for evaluating, monitoring, and portfolio management of new and existing investment opportunities in the portfolios. Prior to joining Eventide in 2024, Mr. White was a Senior Research Analyst at JAT Capital, primarily covering the software sector. Prior to that position, he was an Analyst at Shellback Capital. Mr. White holds a B.A. in Political Science from Middlebury College.

**Eventide Asset Management, LLC**  
One International Place, Suite 4210  
Boston, MA 02110  
877-771-EVEN (3836)  
[WWW.EVENTIDEINVESTMENTS.COM](http://WWW.EVENTIDEINVESTMENTS.COM)

**This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at <https://www.eventidefunds.com/prospectus> or by calling 1-877-771-EVEN (3836). Investors should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.**